JP2004525900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525900A5 JP2004525900A5 JP2002565589A JP2002565589A JP2004525900A5 JP 2004525900 A5 JP2004525900 A5 JP 2004525900A5 JP 2002565589 A JP2002565589 A JP 2002565589A JP 2002565589 A JP2002565589 A JP 2002565589A JP 2004525900 A5 JP2004525900 A5 JP 2004525900A5
- Authority
- JP
- Japan
- Prior art keywords
- buprenorphine
- use according
- medicament
- transdermal therapeutic
- therapeutic system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 51
- 229960001736 buprenorphine Drugs 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 36
- 206010046543 Urinary incontinence Diseases 0.000 claims description 24
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 206010036018 Pollakiuria Diseases 0.000 claims description 18
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
- 208000022934 urinary frequency Diseases 0.000 claims description 10
- 230000036318 urination frequency Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 206010027566 Micturition urgency Diseases 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 5
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 3
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000020629 overactive bladder Diseases 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 239000011505 plaster Substances 0.000 claims description 3
- 230000036592 analgesia Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 4
- 239000007943 implant Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000010410 layer Substances 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000011241 protective layer Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 5
- 230000027939 micturition Effects 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- -1 clenbutarol Chemical compound 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960000855 flavoxate Drugs 0.000 description 1
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000036724 intravesical pressure Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960003510 propiverine Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10107828.5 | 2001-02-16 | ||
| DE2001107828 DE10107828A1 (de) | 2001-02-16 | 2001-02-16 | Verwendung von Buprenorphin zur Therapie der Harninkontinenz |
| DE20115429U DE20115429U1 (de) | 2001-09-18 | 2001-09-18 | Opioide in der Harninkontinenz |
| DE20115429.3 | 2001-09-18 | ||
| DE2001162704 DE10162704A1 (de) | 2001-12-19 | 2001-12-19 | Verwendung von Buprenorphin zur Therapie der Harninkontinenz |
| DE10162704.1 | 2001-12-19 | ||
| PCT/EP2002/001699 WO2002066031A1 (de) | 2001-02-16 | 2002-02-18 | Verwendung von buprenorphin zur therapie der harninkontinenz |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004525900A JP2004525900A (ja) | 2004-08-26 |
| JP2004525900A5 true JP2004525900A5 (https=) | 2010-11-11 |
| JP4908726B2 JP4908726B2 (ja) | 2012-04-04 |
Family
ID=27214302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565589A Expired - Fee Related JP4908726B2 (ja) | 2001-02-16 | 2002-02-18 | ブプレノルフィンを尿失禁の治療に使用する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040102468A1 (https=) |
| EP (1) | EP1368023B1 (https=) |
| JP (1) | JP4908726B2 (https=) |
| AT (1) | ATE314066T1 (https=) |
| AU (1) | AU2002242705B2 (https=) |
| CA (1) | CA2438339C (https=) |
| DE (1) | DE50205438D1 (https=) |
| DK (1) | DK1368023T3 (https=) |
| ES (1) | ES2255607T3 (https=) |
| HU (1) | HU229354B1 (https=) |
| MX (1) | MXPA03006742A (https=) |
| NZ (1) | NZ528064A (https=) |
| PL (1) | PL204638B1 (https=) |
| WO (1) | WO2002066031A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1323421A1 (en) * | 2001-12-20 | 2003-07-02 | Grünenthal GmbH | Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
| US8260389B2 (en) * | 2003-10-15 | 2012-09-04 | Hegln (Dalian) Pharmaceuticals, Inc. | Bladder function monitoring methods, apparatuses, media and signals |
| EP1682002A4 (en) | 2003-10-15 | 2010-03-31 | Univ British Columbia | METHOD AND DEVICE FOR URODYNAMIC ANALYSIS |
| JP6370802B2 (ja) * | 2012-12-28 | 2018-08-08 | テイコク ファーマ ユーエスエー インコーポレーテッド | 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法 |
| EP3067357A1 (en) | 2015-03-11 | 2016-09-14 | Siegfried AG | Method of manufacturing stereoisomers of buprenorphine and analogues thereof |
| CN107320770A (zh) * | 2017-07-12 | 2017-11-07 | 江苏西宏生物医药有限公司 | 一种注射植入剂 |
| EP4613751A1 (en) | 2024-03-07 | 2025-09-10 | Siegfried AG | Method of making chemical compounds useful for the synthesis of buprenorphine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| DE4446600A1 (de) * | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
| DE69631525T2 (de) * | 1995-03-03 | 2004-12-16 | Endo Pharmaceuticals Inc. | Verwendung von dextromethorphan oder dextrorphan zur behandlung der harninkontinenz |
| JPH1036265A (ja) * | 1996-07-19 | 1998-02-10 | Nitto Denko Corp | ブプレノルフィン経皮吸収製剤 |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| IT1302682B1 (it) * | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
-
2002
- 2002-02-18 DE DE50205438T patent/DE50205438D1/de not_active Expired - Lifetime
- 2002-02-18 CA CA2438339A patent/CA2438339C/en not_active Expired - Fee Related
- 2002-02-18 PL PL367401A patent/PL204638B1/pl unknown
- 2002-02-18 DK DK02708327T patent/DK1368023T3/da active
- 2002-02-18 AT AT02708327T patent/ATE314066T1/de active
- 2002-02-18 EP EP02708327A patent/EP1368023B1/de not_active Expired - Lifetime
- 2002-02-18 HU HU0302984A patent/HU229354B1/hu not_active IP Right Cessation
- 2002-02-18 WO PCT/EP2002/001699 patent/WO2002066031A1/de not_active Ceased
- 2002-02-18 ES ES02708327T patent/ES2255607T3/es not_active Expired - Lifetime
- 2002-02-18 MX MXPA03006742A patent/MXPA03006742A/es active IP Right Grant
- 2002-02-18 JP JP2002565589A patent/JP4908726B2/ja not_active Expired - Fee Related
- 2002-02-18 NZ NZ528064A patent/NZ528064A/xx not_active IP Right Cessation
- 2002-02-18 AU AU2002242705A patent/AU2002242705B2/en not_active Ceased
-
2003
- 2003-08-15 US US10/641,296 patent/US20040102468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2670290C (en) | Transdermal therapeutic system for administering the active substance buprenorphine | |
| US6660774B2 (en) | Use of (+)-tramadol, O-demethyltramadol or (+)-O-demethyl-tramadol, O-desmethyl-N-mono-desmethyl-tramadol or (+)- O-desmethyl-N-mono-desmethyltramadol | |
| JP2004525900A5 (https=) | ||
| JP2003520193A (ja) | Ｒ（−）−ケトプロフェンを用いる神経障害性疼痛、耳鳴り、およびその他の障害治療のための方法および組成物 | |
| SK138095A3 (en) | Transdermal therapeutic system for the administration of serotonin agonists | |
| JP2009507076A (ja) | Ｏ−デスメチルベンラファキシン（ｏｄｖ）またはその塩を含有する経皮薬物デリバリーデバイス | |
| JP5094720B2 (ja) | サブスタンス関連障害を処置する方法 | |
| JP4908726B2 (ja) | ブプレノルフィンを尿失禁の治療に使用する方法 | |
| AU2002220736B2 (en) | Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence | |
| JP2022530345A (ja) | 経皮治療システム | |
| CN101631550A (zh) | 带状疱疹后神经痛治疗用片剂以及带状疱疹后神经痛的治疗方法 | |
| JP2003521469A (ja) | 睡眠時無呼吸症を治療する方法 | |
| EP1434574A2 (en) | Tolterodine metabolites | |
| RU2280444C2 (ru) | Применение 6-диметиламинометил-1-фенилциклогексановых соединений для терапии недержания мочи | |
| KR100835874B1 (ko) | 요실금 치료용의 치환된 6-디메틸아미노메틸-1-페닐-사이클로헥산 화합물의 용도 | |
| JP2009507078A (ja) | Ｏ−デスメチルベンラファキシン（ｏｄｖ）またはその塩を含む局所用処方物 | |
| HUE034676T2 (hu) | Gyógyszerkészítmény, amely tartalmaz (1R,4R)-6'fluor- N,N-dimetil-4-fenil-4',9'-dihidro-3'H-spiro[ciklohexán-1,1'-pirano'[3,4,B]indol]-4-amint és paracetamolt vagy propacetamolt | |
| CN114080221A (zh) | 用于减轻疼痛的布洛芬与曲马多的组合 | |
| DE10107828A1 (de) | Verwendung von Buprenorphin zur Therapie der Harninkontinenz | |
| DE10162704A1 (de) | Verwendung von Buprenorphin zur Therapie der Harninkontinenz | |
| DE20115429U1 (de) | Opioide in der Harninkontinenz |